Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures (Medication Study) After Acute Coronary Syndrome Hospital Discharge.

Slides:



Advertisements
Similar presentations
ACTION Registry (Acute Coronary Treatment and Intervention Outcomes Network) Initial Report 1st Quarter 2007 Results Report prepared by: www. ncdr.com.
Advertisements

The results of the Study of Heart and Renal Protection (SHARP)
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: /NEJMSA Niteesh K. Choudhry,
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Main Trial Design and Trial Status
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Nebulized Hypertonic Saline for Bronchiolitis Florin TA, Shaw KN, Kittick M, Yakscoe.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Conclusions: Motivational interviews performed by a trained and specialized nurse staff and ambulatory cardiologic checks in ACS patients improved compliance.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.
Monthly Journal article review: Vimmi Kang PGY 2
IMPACT OF DISPARITIES IN CARDIOVASCULAR CARE ON AFRICAN AMERICAN DEATHS Kevin Fiscella, MD, MPH University of Rochester School of Medicine & Dentistry.
Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:
Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.
The Impact of Different Treatment Strategies on Cardiac Death and MI Rates in Patients with Type 2 Diabetes and Stable Coronary Disease: A Report from.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute ALLHAT Major Outcomes in Moderately.
Federal Study of Adherence to Medications (FAME) Trial Presented at The American Heart Association Annual Scientific Session 2006 Presented by Dr. Allen.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.
RIGHT CARE INITIATIVE TEAM BASED CARE: A LOCAL EXAMPLE 12/10/12 Phillip Raimondi MD Bridget Levich MSN, CDE University of California Davis Medical Center.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Angela Aziz Donnelly April 5, 2016
The OPTImal CArdiac REhabilitation (OPTICARE) trial:
A Clinical profile of patients enrolled in the Pakistan ACS registry
The SPRINT Research Group
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Hypertension in the Post SPRINT era
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
First time a CETP inhibitor shows reduction of serious CV events
Scandinavian Simvastatin Survival Study (4S)
Jeff Macemon Waikato Cardiothoracic Unit
Systolic Blood Pressure Intervention Trial (SPRINT)
Statins Evaluation in Coronary procedUres and REvascularization
European Heart Association Journal 2007 April
Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Monthly Journal article review: Vimmi Kang PGY 2
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Global Registry of Acute Coronary Events: GRACE
Maintenance of Long-Term Clinical Benefit with
Atlantic Cardiovascular Patient Outcomes Research Team
Presentation transcript:

Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures (Medication Study) After Acute Coronary Syndrome Hospital Discharge Ho PM, Lambert-Kerzner A, Carey EP, Fahdi IE, Bryson CL, Melnyk SD, Bosworth HB, Radcliff T, Davis R, Mun H, Weaver J, Barnett C, Barón A, Del Giacco EJ

Disclosures Funded by VHA HSR&D Investigator Initiated Award (IIR ) Dr. Bosworth was supported by a VHA HSR&D Senior Scientist Award (08-027) Dr. Ho is supported by a VHA HSR&D Center of Innovation (1 I50 HX )

Background Adherence to cardiac medications in the year after ACS is poor By 1 month, 1/3 stop at least 1 medication By 1 year, only ~60% are taking statins Adherence <60% even with no co-pay for cardiac medications Poor adherence is associated with adverse outcomes

Objective To test whether a multi-faceted intervention in the year after ACS hospitalization improves adherence to cardiac medications Medication reconciliation and tailoring Patient education Collaborative care Voice messaging

Methods 4 VA sites (Denver, Little Rock, Seattle, Durham) Inclusion criteria: Admitted with ACS (biomarkers, symptoms, ECG) Received usual care at VA Exclusion criteria: Admitted with primary non-cardiac condition Planned discharge to nursing home Limited life expectancy Lack of phone Used of non VA pharmacy

ACS hospitalization (AMI or UA) Hospital discharge: Patients received standard discharge instructions Pharmacist telephone contact Month 1 IVR tele-monitoring and pharmacist contact as needed: Months 2-6: Monthly medication reminder and medication refill calls Months 7-12: Medication refill calls Usual Care Intervention Medication reconciliation with pharmacist 7-10 days 12-month Follow-up visit Study overview

Analysis Primary outcome: Proportion of patients adherent (PDC>0.80)based on average PDC of cardiac medications at 12-months PDC: number of days supplied over the number of days of follow-up ß-blockers, statins, clopidogrel, ACE-I/ARB Secondary outcome: BP and LDL goals Tertiary outcome: MI, death, revascularization Sample size: 280 patients to have 80% power to detect 15% difference in proportion adherent

789 patients assessed for eligibility 536 patients excluded 428 not meeting inclusion criteria No ACS: 152 Study Defined Exclusion Criteria: refused to participate 129 Assigned to Receive Intervention124 Assigned to Receive Usual Care Intervention Patients Excluded: 5 patients withdrawn 2 No medication data Control Patients Excluded: 3 patients withdrawn 2 No medication data 122 Intervention Patients119 Usual Patients 253 patients randomized

Baseline characteristics were comparable VariableUsual CareIntervention N Subjects Age, Mean (SD)64.0 (8.6)63.8 (9.2) Diabetes mellitus (%)39.5%50.8% Prior Heart Failure (%)10.9%13.9% Chronic Kidney Disease (%)23.5%23.0% Chronic Lung Disease (%)19.3%20.5% Prior CAD (%)66.4%64.8% Type of ACS STEMI12.6%14.8% NSTEMI30.3%28.7% Unstable angina57.1%56.6% In-hospital revascularization PCI (%)39.8%43.8% Drug eluting stent(%)84.1%78.9% CABG (%)17.1%6.7%* * p<0.05

Primary outcome: Higher adherence in intervention Proportion with average PDC >0.80 NS * * * * p<0.05 Proportion with PDC >0.80

Sensitivity analysis: Adherence higher in intervention PDC >0.80 for all medications Proportion with PDC >0.80 Primary outcomeSensitivity analysis *

Sensitivity analysis: Adherence higher in intervention Mean PDC NS * * * * p<0.05 Mean PDC

No difference in clinical outcomes at 12- months (BP, LDL, revascularization, MI and death) Outcome Usual CareIntervention p-value Achieved BP goal (%) a 49%59% 0.23 LDL <100 mg/dl b 83%72% 0.14 Mortality %7.6%9.0%0.86 MI (%)4.2%6.6%0.60 Revascularization (%)17.6%11.5%0.24 BP goal: BP<140/90 mm Hg and <130/80 mm Hg for DM and CKD a: 94% had BP data b: 63% had LDL data

Modest intervention costs and similar total costs at 12-months CostsUsual CareInterventionP-value Intervention$0$360 Cardiac medications$663$ Total medications$2,724$2, Total outpatient$11,691$13, Total inpatient$14,287$11, Total (intervention, medication, outpatient, and inpatient) $19,989$19,

Limitations Predominantly males within an integrated health care system Highly adherent patients Relatively short duration of follow-up

Conclusions Multi-faceted intervention improved adherence to cardiac medication after ACS No difference in the clinical outcomes Modest cost of the intervention over the 1 year period Important to understand impact of improvement in adherence on clinical outcomes

jamanetwork.com Available at jamainternalmedicine.com and on The JAMA Network Reader at mobile.jamanetwork.com JAMA Internal Medicine P. Michael Ho and coauthors Title: Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures After Acute Coronary Syndrome Hospital Discharge: A Randomized Clinical Trial Published online November 18, 2013

Lipids and adherence Patients with close-out lipid panel were more likely to be adherent 96.2% vs. 74.2% (p=0.03) Differential lipid testing 66.4% vs. 59.7% (Int vs. UC) Adherent patients had ng/dl lower LDL compared to non-adherent patients regardless of treatment group

Additional LDL analysis Outcome Usual CareIntervention Statin adherentNo (n=17)Yes (n=43)No (n=5)Yes (n=64) LDL change, mg/dl (SD)-9.3 (39.1)-13.1 (28.7)+15.4 (28.6)-15.5 (38.2) LDL end of study, mg/dl (SD)88.8 (27.8)73.2 (23.2)114.4 (29.7)77.0 (31.7) Outcome Usual CareIntervention p-value LDL <100 mg/dl (%) 59/71 (83%)58/81 (72%) 0.14 LDL mg/dl, mean (SD) 76 (25)80 (32) 0.37 Change in LDL mg/dl, mean (SD) -12 (31)-13 (38) 0.90

Additional BP analysis Outcome Usual CareIntervention p-value BP<140/90 (<130/80 for DM or CKD) mm Hg (%) 49% (46/94 a ) 59% (58/99 a ) 0.23 Systolic BP, mean (SD) 132 (21)130 (20) 0.50 Diastolic BP, mean (SD) 75 (12)76 (12) 0.50 Change in systolic BP, mean (SD) -4 (27)-12 (27) 0.07 Change in diastolic BP, mean (SD) -3 (18)-5 (16) 0.39 Usual CareIntervention Overall AdherentNoYesNoYes SBP change Mean SBP DBP change Mean DBP

Data on automated calls Total number of calls per patient (8.8) Refill calls (6.2) Educational calls- 7.2 (3.9) Human (8.1) Answering machine- 5.3 (4.7) Correlation between average PDC and total number of calls (0.15; NS)